Biologic disease-modifying antirheumatic drug (bdmard)-induced neutropenia: A registry from a retrospective cohort of patients with rheumatic diseases treated with 3 classes of intravenous bdmard

Journal of Rheumatology

Volumn 44, Issue 6, 2017, Pages 844-849

  Espinoza, Francisco ^a,b   Le Blay, Pierre ^a   Combe, Bernard ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b UNIVERSIDAD DE LOS ANDES   (Chile)

Author keywords

ANTIRHEUMATIC AGENTS; INFECTION; NEUTROPENIA; TOCILIZUMAB

Indexed keywords

ABATACEPT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; INFECTION RISK; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SPONDYLARTHRITIS; SURVIVAL TIME; THROMBOCYTOPENIA; AGED; CHEMICALLY INDUCED; MIDDLE AGED; REGISTER; VERY ELDERLY;

ABATACEPT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; INFLIXIMAB; MALE; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; REGISTRIES; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES;

EID: 85020229162     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150457     Document Type: Article

References (22)

1. Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther 2012;36:312-23.
2. Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 2003;139:W-W63.
3. US National Cancer Institute. Common toxicity criteria manual, version 2.0. Bethesda: NCI; 1999.
4. Hastings R, Ding T, Butt S, Gadsby K, Zhang W, Moots RJ, et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res 2010;62:764-9.
5. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
6. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
7. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009;68:1708-14.
8. Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011;70:1826-30.
9. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
10. Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 2002;25:173-97.
11. Montané E, Sallés M, Barriocanal A, Riera E, Costa J, Tena X. Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. Clin Rheumatol 2007;26:1527-9.
12. Wenham C, Gadsby K, Deighton C. Three significant cases of neutropenia with etanercept [letter]. Rheumatology 2008;47:376-7.
13. Rajakulendran S, Gadsby K, Allen D, O'Reilly S, Deighton C. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis [letter]. Ann Rheum Dis 2006;65:1678-9.
14. Pappas DA, Shaw JW, Chang H, Cifaldi MA, Reed GW, Garg V, et al. Laboratory safety of adalimumab and other tumor necrosis factor inhibitors in the treatment of rheumatoid arthritis [abstract]. Ann Rheum Dis 2014;73 Suppl 2:931.
15. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
16. De Benedetti F, Rubio-Pérez N, Salazar CD, Goodman S, Job-Deslandre C, Joos R, et al. A45: neutropenia with tocilizumab treatment is not associated with increased infection risk in patients with polyarticular-course juvenile idiopathic arthritis [abstract]. Arthritis Rheumatol 2014;66 Suppl 3:S67-8.
17. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
18. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
19. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
20. Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69-74.
21. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
22. Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology 2014;53:1321-31.